Videos

$Current Therapeutic Paradigm for Relapsed-Refractory CLL$

Current Therapeutic Paradigm for Relapsed-Refractory CLL

Watch

Optimizing Frontline Therapy Selection and Follow-Up in CLL

Optimizing Frontline Therapy Selection and Follow-Up in CLL

Watch

Venetoclax's Role in Frontline CLL Management

Venetoclax's Role in Frontline CLL Management

Watch

CLL: Patient Evaluation and Risk Stratification

CLL: Patient Evaluation and Risk Stratification

Watch

BCL2 Inhibition in Leukemia

BCL2 Inhibition in Leukemia

Leukemia

Watch

Triplet Regimen Improves Responses in BRAF V600E+ Metastatic CRC

Triplet Regimen Improves Responses in BRAF V600E+ Metastatic CRC

Tanios Bekaii-Saab, MD, discusses the results from the phase III BEACON CRC study; investigators evaluated the efficacy and safety of triplet encorafenib, binimetinib, and cetuximab in patients with BRAF V600E–mutant metastatic colorectal cancer who previously received up to 2 lines of prior therapy.

Watch

Challenges in Management of Chronic Phase CML

Challenges in Management of Chronic Phase CML

Watch

Treatment-Free Remission & Toxicities of Discontinuing CML Therapy

Treatment-Free Remission & Toxicities of Discontinuing CML Therapy

Watch

Dose-Related Adverse Events With Ponatinib When Treating CML

Dose-Related Adverse Events With Ponatinib When Treating CML

Watch

Adverse Events of Second-Generation TKIs Used in Treating CML

Adverse Events of Second-Generation TKIs Used in Treating CML

Watch

Bosutinib Versus Ponatinib in R/R CML

Bosutinib Versus Ponatinib in R/R CML

Watch

Early Intervention With Ponatinib in Treatment of CML

Early Intervention With Ponatinib in Treatment of CML

Watch

Role of Ponatinib in Treatment of R/R CML

Role of Ponatinib in Treatment of R/R CML

Watch

Frontline Treatment for CML With BCR-ABL-Targeted TKIs

Frontline Treatment for CML With BCR-ABL-Targeted TKIs

Watch

Resistance to Targeted-TKI Treatment in Patients With CML

Resistance to Targeted-TKI Treatment in Patients With CML

Watch

Importance of Compliance With TKIs in Treatment of CML

Importance of Compliance With TKIs in Treatment of CML

Watch

Response Monitoring of Patients With CML Treated With TKIs

Response Monitoring of Patients With CML Treated With TKIs

Watch

BCR-ABL1-Targeted TKIs in Treatment of CML

BCR-ABL1-Targeted TKIs in Treatment of CML

Watch

CML as an Ideal Cancer for Targeted Therapy With TKI

CML as an Ideal Cancer for Targeted Therapy With TKI

Watch

$BCR-ABL1 TKIs in Relapsed/Refractory CML$

BCR-ABL1 TKIs in Relapsed/Refractory CML

Chronic Myeloid Leukemia

Watch

The Future of BTK Inhibition in B-Cell Lymphomas

The Future of BTK Inhibition in B-Cell Lymphomas

Watch

Treating With BTK Inhibitors in Practice

Treating With BTK Inhibitors in Practice

Watch

BTK Inhibitors: Infections and Secondary Malignancies

BTK Inhibitors: Infections and Secondary Malignancies

Watch

BTK Inhibitors and Toxicity Management in B-Cell Lymphomas

BTK Inhibitors and Toxicity Management in B-Cell Lymphomas

Watch

Selecting Between Targeted Therapies in B-Cell Lymphomas

Selecting Between Targeted Therapies in B-Cell Lymphomas

Watch

BTK Inhibitors in Other B-cell Lymphomas

BTK Inhibitors in Other B-cell Lymphomas

Watch

BTK Inhibitors in Mantle Cell Lymphoma

BTK Inhibitors in Mantle Cell Lymphoma

Watch

Other BTK Inhibitors in Chronic Lymphocytic Leukemia

Other BTK Inhibitors in Chronic Lymphocytic Leukemia

Watch

Ibrutinib Therapy in Chronic Lymphocytic Leukemia

Ibrutinib Therapy in Chronic Lymphocytic Leukemia

Watch

BTK Inhibitors as Treatment for B-Cell Lymphomas

BTK Inhibitors as Treatment for B-Cell Lymphomas

Watch

...

192 193 194 195 196 197 198 199 200

...

CancerNetwork.com

OncNursingNews.com

Do Not Sell My Information

Terms & Conditions

Contact Info

2 Commerce Drive
Cranbury, NJ 08512

© 2024 MJH Life Sciences

All rights reserved.